Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and Exposition

SOUTH SAN FRANCISCO, Calif., Nov. 3, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that data from the ongoing Phase 1b study of R289¹, a potent and selective inhibitor of dual interleukin receptor-associated kinases 1 and 4 (IRAK1/4), in patients with lower-risk myelodysplastic syndrome (MDS) who are relapsed or refractory (R/R) to prior therapies will be presented in an oral session at the 67^th American Society of Hematology (ASH) Annual Meeting and Exposition on Sunday, December 7, 2025. In addition, the ASH Annual Meeting will feature four poster presentations with data for REZLIDHIA^® (olutasidenib) for the treatment of R/R mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AML). The ASH Annual Meeting is being held December 6-9, 2025, in Orlando, Florida and virtually.

Read more at prnewswire.com